Targeted Identification of Sialoglycoproteins in Hypoxic Endothelial Cells and Validation in Zebrafish Reveal Roles for Proteins in Angiogenesis

Delcourt, Nicolas; Quevedo, Celia; Nonne, Christelle; Fons, Pierre; O'Brien, Donogh P.; Loyaux, Denis; Diez, Maria; Autelitano, François; Guillemot, Jean‐Claude; Ferrara, Pascual; Muriana, Arantza; Callol, Carles; Hérault, Jean-Pascal; Herbert, Jean‐Marc; Favre, Gilles; Bono, Françoise

doi:10.1074/jbc.m114.618611

Cited by 23 publications

(19 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is consistent with previous findings, as shear stress is lower in blood vessels containing atherosclerotic plaques when compared with healthy controls . CLEC14A expression has also been linked with hypoxia in HUVEC, and could explain its greater expression in the tumour vasculature .…”

Section: Clec14a Expressionsupporting

confidence: 93%

C‐type lectin domain group 14 proteins in vascular biology, cancer and inflammation

et al. 2019

View full text Add to dashboard Cite

The C‐type lectin domain (CTLD) group 14 family of transmembrane glycoproteins consist of thrombomodulin, CD93, CLEC14A and CD248 (endosialin or tumour endothelial marker‐1). These cell surface proteins exhibit similar ectodomain architecture and yet mediate a diverse range of cellular functions, including but not restricted to angiogenesis, inflammation and cell adhesion. Thrombomodulin, CD93 and CLEC14A can be expressed by endothelial cells, whereas CD248 is expressed by vasculature associated pericytes, activated fibroblasts and tumour cells among other cell types. In this article, we review the current literature of these family members including their expression profiles, interacting partners, as well as established and speculated functions. We focus primarily on their roles in the vasculature and inflammation as well as their contributions to tumour immunology. The CTLD group 14 family shares several characteristic features including their ability to be proteolytically cleaved and engagement of some shared extracellular matrix ligands. Each family member has strong links to tumour development and in particular CD93, CLEC14A and CD248 have been proposed as attractive candidate targets for cancer therapy.

show abstract

Section: Clec14a Expressionsupporting

confidence: 93%

C‐type lectin domain group 14 proteins in vascular biology, cancer and inflammation

et al. 2019

View full text Add to dashboard Cite

show abstract

“…To examine the effects of CLEC14A deficiency on EC sprouting and angiogenesis in the absence of confounding factors, we performed ex vivo aortic ring assays and Matrigel plug under hypoxic conditions as well as in circulating ECs of cancer patients (8,(16)(17)(18). Furthermore, CLEC14A regulates sprouting angiogenesis by shedding its ectodomain, which is catalyzed by rhomboid-like 2 protein (19).…”

Section: Introductionmentioning

confidence: 99%

Carbohydrate-binding protein CLEC14A regulates VEGFR-2– and VEGFR-3–dependent signals during angiogenesis and lymphangiogenesis

Lee

Rho

Park

et al. 2016

Journal of Clinical Investigation

View full text Add to dashboard Cite

“…Considering the necessity of vessel formation in tumor growth, invasion and metastasis, a label-free quantitative proteomic study was conducted using HUVECs under hypoxic conditions. Twenty-seven sialoglycoproteins on the surface of HUVECs were identified as overexpressed (68), in addition to the CD105, neuropilin-1 and CLEC14A proteins that had been previously described by other studies of hypoxia (69-71).…”

Section: Label-free Quantitative Msmentioning

confidence: 62%

Progress in mass spectrometry-based proteomic research of tumor hypoxia

Gao

Luo

2017

Oncology Reports

View full text Add to dashboard Cite

A hypoxic microenvironment effects various signaling pathways in the human body, including those that are critical for normal physiology and those that support tumorigenesis or cancer progression. A hypoxic tumor microenvironment, in particular, modulates cell migration, invasion and resistance to radiotherapy and chemotherapy. Development of the mass spectrometry (MS) technique has allowed for expansion of proteomic study to a wide variety of fields, with the study of tumor hypoxia being among the latest to enjoy its benefits. In such studies, changes in the proteome of tumor tissue or cells induced by the hypoxic conditions are analyzed. A multitude of hypoxic regulatory proteins have already been identified, increasing our understanding of the mechanisms underlying tumor occurrence and development and representing candidate reference markers for tumor diagnosis and therapy. The present review provides the first summary of the collective studies on tumor microenvironment hypoxia that have been completed using MS-based proteomic techniques, providing a systematic discussion of the benefits and current challenges of the various applications.

show abstract

Targeted Identification of Sialoglycoproteins in Hypoxic Endothelial Cells and Validation in Zebrafish Reveal Roles for Proteins in Angiogenesis

Cited by 23 publications

References 41 publications

C‐type lectin domain group 14 proteins in vascular biology, cancer and inflammation

C‐type lectin domain group 14 proteins in vascular biology, cancer and inflammation

Carbohydrate-binding protein CLEC14A regulates VEGFR-2– and VEGFR-3–dependent signals during angiogenesis and lymphangiogenesis

Progress in mass spectrometry-based proteomic research of tumor hypoxia

Contact Info

Product

Resources

About